ITM-91 by ITM Isotope Technologies Munich for Metastatic Colorectal Cancer: Likelihood of Approval

ITM-91 is under clinical development by ITM Isotope Technologies Munich and currently in Phase II for Metastatic Colorectal Cancer.

Ascentage’s olverembatinib gains approval in Macau for leukaemia

Ascentage Pharma’s olverembatinib is indicated for the treatment of haematological malignancy indications. Credit: Nemes Laszlo / Shutterstock. Ascentage Pharma has obtained approval for its new

July 8, 2024

Overcoming challenges in COPD care: study focuses on pulmonary rehabilitation strategies

The different perspectives of respiratory care professionals.

August 4, 2023

How Do You Select Systemic Therapy for Your Psoriasis Patients?

In this exclusive MedPage Today video, Richard Warren, MBChB, PhD, professor of Dermatology at the University of Manchester in England, explains how he approaches selecting

December 13, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.